Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment
| Authors | |
|---|---|
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Cancer Immunology and Immunotherapy |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.ncbi.nlm.nih.gov/pubmed/29748897 |
| Doi | http://dx.doi.org/10.1007/s00262-018-2166-4 |
| Keywords | myeloid-derived suppresor cells; granulocyty colony-stimulating factor; cancer; prophylaxis of febrile neutropenia; CITIM 2017 |
| Attached files | |
| Description | Myeloid-derived suppressor cells (MDSCs) have been shown to contribute to tumor escape from host immune surveillance and to cancer progression by production of tumor-promoting soluble factors. Granulocyte colony-stimulating factor (G-CSF) is a principle cytokine controlling granulocyte number. Recombinant human G-CSF (rhG-CSF) has become the main therapeutic agent for the treatment of neutropenia and prophylaxis of febrile neutropenia in cancer patients. However, we show here that rhG-CSF triggers accumulation of granulocytic and monocytic subsets. Consequently, we discuss the pharmacological use of granulopoiesis stimulating factors not only in the context of febrile neutropenia but also from the perspective of MDSC-dependent and MDSC-independent mechanisms of immunosuppression and cancer angiogenesis. |
| Related projects: |